Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03502161 · ClinicalTrials.gov registry record
Clinical Evaluation of the QuantiFERON CMV Assay
A clinical trial, sponsored by QIAGEN Gaithersburg.
- Terminated
- Registry status
- 8
- Enrollment target
NCT03502161: Clinical Trial study, sponsored by QIAGEN Gaithersburg.
NCT03502161 is a clinical trial that was terminated before completion, run by QIAGEN Gaithersburg. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03502161 was terminated before completion, sponsored by QIAGEN Gaithersburg.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Validate the use of the device in the clinical setting for assessing the risk of CMV Infection in SOT recipients after the completion of antiviral prophylaxis.
Primary Outcome
Measurement of QF-CMV result
Interventions
- DEVICE QuantiFERON CMV Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2020-06-30 |
Why NCT03502161 stopped before completion
NCT03502161 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which QuantiFERON CMV Assay is the first listed.
NCT03502161 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03502161 about?
NCT03502161 is a clinical study titled "Clinical Evaluation of the QuantiFERON CMV Assay". Validate the use of the device in the clinical setting for assessing the risk of CMV Infection in SOT recipients after the completion of antiviral prophylaxis.
What is the current status of trial NCT03502161?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2018-11-15. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03502161?
The interventions under investigation include: QuantiFERON CMV Assay (DEVICE).
Who is sponsoring clinical trial NCT03502161?
This trial is sponsored by QIAGEN Gaithersburg, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI